Xin Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xin Deng has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Hai Qian
China Pharmaceutical University
10 shared publications - Wenlong Huang
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, China
9 shared publications Chenyu Zhang
State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Department of Pharmacy, Guangzhou Chest Hospital, Institute of Tuberculosis Guangzhou Medical University Guangzhou China
8 shared publicationsXuekun Wang
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, China
7 shared publicationsBaowei Yang
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, China
5 shared publicationsHonglan Zhong
State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Department of Pharmacy, Guangzhou Chest Hospital, Institute of Tuberculosis Guangzhou Medical University Guangzhou China
4 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 12, 100681
The lipid nanomicelles incorporating peptide vaccine and SN38 prodrug potentiate neoadjuvant chemo-immunotherapy
- 9 October 2026
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 12, 100681
Open AccessThe lipid nanomicelles incorporating peptide vaccine and SN38 prodrug potentiate neoadjuvant chemo-immunotherapy
- Open Access
- 15 September 2026
- Published by Wiley in Advanced Intelligent Discovery
- p. e70159
A Multistrategy AI‐Assisted Consensus Screening Pipeline for Discovery of Candidate p53 Monomer Binders
The rapid advancement of AI has greatly boosted the efficiency of large‐scale lead compound screening, especially for proteins without resolved 3D structures in the PDB. However, current large structure databases cannot support efficient large‐scale screening within drug R&D cycles. Here, we propose a multistrategy consensus screening pipeline and establish a corresponding small‐sample rapid screening system to identify candidate mini binders as potential lead ligands for the tumor suppressor p53 monomer. Using AI models, we predicted the p53 monomer structure and built a 500‐mini‐protein library. Protein–protein docking, co‐folding, and energy scoring were integrated into the consensus screening pipeline, with the PD‐L1&VHH6 complex as a positive control. Through comprehensive computational evaluation via the constructed consensus screening pipeline, A0A0R0G186 was determined as the optimal hit candidate with a calculated interfacial hydrophobic energy density ( γ bind = −3.47 kcal mol −1 Å −2 ). Structural alignment demonstrates that its key binding region shows high structural similarity to the native protein A0A0R0G186 (RMSD = 0.34 Å). The candidate protein exhibits a predicted amyloid formation probability of 0.787, a large proportion of soluble regions, and a reasonable hydrophobic core distribution, which computationally indicates favorable druggability potential. Notably, all the above findings are computational predictions that require further systematic experimental validation.
- 15 September 2026
- Published by Wiley in Advanced Intelligent Discovery
- p. e70159
Open AccessA Multistrategy AI‐Assisted Consensus Screening Pipeline for Discovery of Candidate p53 Monomer Binders
The rapid advancement of AI has greatly boosted the efficiency of large‐scale lead compound screening, especially for proteins without resolved 3D structures in the PDB. However, current large structure databases cannot support efficient large‐scale screening within drug R&D cycles. Here, we propose a multistrategy consensus screening pipeline and establish a corresponding small‐sample rapid screening system to identify candidate mini binders as potential lead ligands for the tumor suppressor p53 monomer. Using AI models, we predicted the p53 monomer structure and built a 500‐mini‐protein library. Protein–protein docking, co‐folding, and energy scoring were integrated into the consensus screening pipeline, with the PD‐L1&VHH6 complex as a positive control. Through comprehensive computational evaluation via the constructed consensus screening pipeline, A0A0R0G186 was determined as the optimal hit candidate with a calculated interfacial hydrophobic energy density ( γ bind = −3.47 kcal mol −1 Å −2 ). Structural alignment demonstrates that its key binding region shows high structural similarity to the native protein A0A0R0G186 (RMSD = 0.34 Å). The candidate protein exhibits a predicted amyloid formation probability of 0.787, a large proportion of soluble regions, and a reasonable hydrophobic core distribution, which computationally indicates favorable druggability potential. Notably, all the above findings are computational predictions that require further systematic experimental validation.
- Open Access
- 12 June 2026
- Published by Elsevier in SSRN Electronic Journal
The Lipid Nanomicelles Incorporating Peptide Vaccine and SN38 Prodrug Potentiate Neoadjuvant Chemo-Immunotherapy
Neoadjuvant regimens often fail to eliminate micrometastases due to profound immunosuppression and the limited immunogenicity of residual tumor cells. In this work, a versatile lipid nanoplatform (SFE/SFA) were engineered to orchestrate potent chemotherapy with in situ neoantigen vaccination. Unlike conventional physical encapsulation, an arginine-modified SN38 prodrug (SN38-Arg) was synthesized to enhance amphiphilicity and facilitate the co-assembly with PEGylated lipids and tumor-specific peptides (HPV16 E7 or Adpgk). This design yields uniform ~115 nm nanomicelles with exceptional stability and >60% peptide loading efficiency. Mechanistically, these nanomicelles leverage folate-receptor targeting to achieve dual synchronization: SN38-Arg induces Topoisomerase I inhibition and extensive DNA damage, while simultaneously promoting dendritic cell maturation and antigen cross-presentation. In neoadjuvant murine models of HPV+ TC-1 and MSI-high MC38 tumors, a brief preoperative course of SFE/SFA not only significantly debulked primary tumors but, critically, prevented postsurgical recurrence in 100% of treated cohorts and established long-term protective memory T cell reservoirs. This was accompanied by a remodeled tumor immune microenvironment marked by elevated CD8+ T cell infiltration and the reduction of regulatory T cells and MDSCs, all without discernible systemic toxicity. This work establishes a clinically translatable, off-the-shelf nanomicellar strategy that integrates SN38-based chemotherapy with peptide vaccination, offering a compelling avenue to improve pathological complete response rates and long-term disease-free survival in surgical oncology.
- 12 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Lipid Nanomicelles Incorporating Peptide Vaccine and SN38 Prodrug Potentiate Neoadjuvant Chemo-Immunotherapy
Neoadjuvant regimens often fail to eliminate micrometastases due to profound immunosuppression and the limited immunogenicity of residual tumor cells. In this work, a versatile lipid nanoplatform (SFE/SFA) were engineered to orchestrate potent chemotherapy with in situ neoantigen vaccination. Unlike conventional physical encapsulation, an arginine-modified SN38 prodrug (SN38-Arg) was synthesized to enhance amphiphilicity and facilitate the co-assembly with PEGylated lipids and tumor-specific peptides (HPV16 E7 or Adpgk). This design yields uniform ~115 nm nanomicelles with exceptional stability and >60% peptide loading efficiency. Mechanistically, these nanomicelles leverage folate-receptor targeting to achieve dual synchronization: SN38-Arg induces Topoisomerase I inhibition and extensive DNA damage, while simultaneously promoting dendritic cell maturation and antigen cross-presentation. In neoadjuvant murine models of HPV+ TC-1 and MSI-high MC38 tumors, a brief preoperative course of SFE/SFA not only significantly debulked primary tumors but, critically, prevented postsurgical recurrence in 100% of treated cohorts and established long-term protective memory T cell reservoirs. This was accompanied by a remodeled tumor immune microenvironment marked by elevated CD8+ T cell infiltration and the reduction of regulatory T cells and MDSCs, all without discernible systemic toxicity. This work establishes a clinically translatable, off-the-shelf nanomicellar strategy that integrates SN38-based chemotherapy with peptide vaccination, offering a compelling avenue to improve pathological complete response rates and long-term disease-free survival in surgical oncology.
- 1 June 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (6) , e70289
Chaperone‐Mediated Autophagy‐Directed Degradation of PI3K in Tumor Cells: Development of Multifunctional Peptide‐Drug Conjugates With Enhanced Penetration and Selectivity
The phosphatidylinositol 3‐kinase (PI3K) pathway is frequently hyperactivated in cancers, promoting tumor growth and resistance to conventional therapies. Conventional PI3K inhibitors often suffer from poor tumor selectivity, systemic toxicity, and the development of acquired resistance. To overcome these issues, we have designed multifunctional peptide‐drug conjugates (PDCs) utilizing chaperone‐mediated autophagy (CMA), a selective lysosomal degradation mechanism, for precise targeting of PI3K. Our approach began with the development of a lead compound, CC‐3, derived from Copanlisib and incorporating a CMA‐recognition motif (KFERQ‐like sequence). We further enhanced this compound by creating TCCC‐1, integrating a tumor‐homing peptide (Thx) and a cell‐penetrating peptide (T2) to improve cellular uptake and specificity. In vitro studies revealed that TCCC‐1 effectively induced PI3K degradation, inhibited downstream pAkt signaling, and promoted apoptosis alongside G2/M cell cycle arrest in non‐small cell lung cancer (NSCLC) cells, including those resistant to Copanlisib. In vivo experiments using NCI‐H460 xenograft models demonstrated that TCCC‐1 achieved up to 97.0% tumor suppression at high doses, surpassing the efficacy of Copanlisib, without causing significant systemic toxicity, organ damage, or metabolic disturbances such as hyperglycemia. These results highlight TCCC‐1 as a promising therapeutic candidate that leverages CMA for precise PI3K degradation, offering enhanced penetration and selectivity against tumors.
- 1 June 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (6) , e70289
Chaperone‐Mediated Autophagy‐Directed Degradation of PI3K in Tumor Cells: Development of Multifunctional Peptide‐Drug Conjugates With Enhanced Penetration and Selectivity
The phosphatidylinositol 3‐kinase (PI3K) pathway is frequently hyperactivated in cancers, promoting tumor growth and resistance to conventional therapies. Conventional PI3K inhibitors often suffer from poor tumor selectivity, systemic toxicity, and the development of acquired resistance. To overcome these issues, we have designed multifunctional peptide‐drug conjugates (PDCs) utilizing chaperone‐mediated autophagy (CMA), a selective lysosomal degradation mechanism, for precise targeting of PI3K. Our approach began with the development of a lead compound, CC‐3, derived from Copanlisib and incorporating a CMA‐recognition motif (KFERQ‐like sequence). We further enhanced this compound by creating TCCC‐1, integrating a tumor‐homing peptide (Thx) and a cell‐penetrating peptide (T2) to improve cellular uptake and specificity. In vitro studies revealed that TCCC‐1 effectively induced PI3K degradation, inhibited downstream pAkt signaling, and promoted apoptosis alongside G2/M cell cycle arrest in non‐small cell lung cancer (NSCLC) cells, including those resistant to Copanlisib. In vivo experiments using NCI‐H460 xenograft models demonstrated that TCCC‐1 achieved up to 97.0% tumor suppression at high doses, surpassing the efficacy of Copanlisib, without causing significant systemic toxicity, organ damage, or metabolic disturbances such as hyperglycemia. These results highlight TCCC‐1 as a promising therapeutic candidate that leverages CMA for precise PI3K degradation, offering enhanced penetration and selectivity against tumors.
- 22 June 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (6) , e70021
DiWB‐1: A Luteinizing Hormone Releasing Hormone (LHRH)‐Targeted Peptide‐Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy
Phosphoinositide 3‐kinase (PI3K) inhibitors have demonstrated efficacy in cancer therapy; yet, their clinical use is often restricted by off‐target toxicity. Peptide‐drug conjugates (PDCs) have emerged as a strategy to improve tumor selectivity by targeting receptors overexpressed in malignant cells. Luteinizing hormone‐releasing hormone receptors (LHRHR), upregulated in several cancers, present an attractive target for such approaches. In this study, we obtained an LHRHR‐targeting peptide IV‐6, characterized by high receptor affinity and robust metabolic stability. IV‐6 was then conjugated to the PI3K inhibitor buparlisib, forming the target PDC, DiWB‐1. In Vitro, DiWB‐1 exhibited superior antineoplastic effects against LHRHR‐positive MDA‐MB‐231 cells, with an IC50 of 1.8 μM, compared with 2.4 μM for buparlisib, and demonstrated reduced toxicity in normal cells. In Vivo, DiWB‐1 showed considerable tumor‐suppressive effects while minimizing systemic toxicity, avoiding the hepatic and renal damage, as well as hyperglycemia, observed with buparlisib treatment. Pharmacokinetic studies further indicated that DiWB‐1 had favorable metabolic stability, with a half‐life of 5.6 h, slightly exceeding that of triptorelin (4.2 h). These findings suggest that DiWB‐1 holds promise as a selective, potent, and long‐acting anticancer PDC, warranting further investigation.
- 22 June 2025
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (6) , e70021
DiWB‐1: A Luteinizing Hormone Releasing Hormone (LHRH)‐Targeted Peptide‐Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy
Phosphoinositide 3‐kinase (PI3K) inhibitors have demonstrated efficacy in cancer therapy; yet, their clinical use is often restricted by off‐target toxicity. Peptide‐drug conjugates (PDCs) have emerged as a strategy to improve tumor selectivity by targeting receptors overexpressed in malignant cells. Luteinizing hormone‐releasing hormone receptors (LHRHR), upregulated in several cancers, present an attractive target for such approaches. In this study, we obtained an LHRHR‐targeting peptide IV‐6, characterized by high receptor affinity and robust metabolic stability. IV‐6 was then conjugated to the PI3K inhibitor buparlisib, forming the target PDC, DiWB‐1. In Vitro, DiWB‐1 exhibited superior antineoplastic effects against LHRHR‐positive MDA‐MB‐231 cells, with an IC50 of 1.8 μM, compared with 2.4 μM for buparlisib, and demonstrated reduced toxicity in normal cells. In Vivo, DiWB‐1 showed considerable tumor‐suppressive effects while minimizing systemic toxicity, avoiding the hepatic and renal damage, as well as hyperglycemia, observed with buparlisib treatment. Pharmacokinetic studies further indicated that DiWB‐1 had favorable metabolic stability, with a half‐life of 5.6 h, slightly exceeding that of triptorelin (4.2 h). These findings suggest that DiWB‐1 holds promise as a selective, potent, and long‐acting anticancer PDC, warranting further investigation.
- 24 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 284, 117204
Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy
- 24 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 284, 117204
Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy
- 9 September 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 645, 123402
Design, synthesis and bioactivity investigation of peptide-camptothecin conjugates as anticancer agents with a potential to overcome drug resistance
- 9 September 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 645, 123402
Design, synthesis and bioactivity investigation of peptide-camptothecin conjugates as anticancer agents with a potential to overcome drug resistance
- 10 December 2022
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 631, 122483
Plasma metabolites-based design of long-acting peptides and their anticancer evaluation
- 10 December 2022
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 631, 122483
Plasma metabolites-based design of long-acting peptides and their anticancer evaluation
- 5 April 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (7) , 5850-5865
Design, Synthesis, and Bioevaluation of Novel Enzyme-Triggerable Cell Penetrating Peptide-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy
Novel enzyme-triggerable cell penetrating peptide (ETCPP) dendrimers with a camptothecin (CPT) warhead were designed and synthesized based on an amphiphilic penetrating peptide (FKKFFRKLL, discovered by us before). Among the newly synthesized ETCPP dendrimer conjugates, BL_Oc-SS-CPT (a high-generation dendrimer) exhibited the highest activity with IC50s in the nanomolar range (31–747 nM) against a panel of cancer cells, which is 3–10 times better than that of CPT. BL_Oc-SS-CPT remained intact during transit to target cells and in normal tissues with a plasma half-life of 4.2 h, 2.3-fold longer than that of the monomer (1.8 h). Once reaching the tumor site, BL_Oc-SS-CPT gradually released CPT in the presence of excessive matrix metalloproteinase-2/9 and GSH in cancer cells. Importantly, BL_Oc-SS-CPT exhibited excellent in vivo tumor targeting capability and antitumor efficacy with benign toxicity profiles. Thus, the novel ETCPP dendrimer-based drug delivery system (e.g., BL_Oc-SS-CPT) represents a safe and effective strategy for targeted cancer therapy.
- 5 April 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (7) , 5850-5865
Design, Synthesis, and Bioevaluation of Novel Enzyme-Triggerable Cell Penetrating Peptide-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy
Novel enzyme-triggerable cell penetrating peptide (ETCPP) dendrimers with a camptothecin (CPT) warhead were designed and synthesized based on an amphiphilic penetrating peptide (FKKFFRKLL, discovered by us before). Among the newly synthesized ETCPP dendrimer conjugates, BL_Oc-SS-CPT (a high-generation dendrimer) exhibited the highest activity with IC50s in the nanomolar range (31–747 nM) against a panel of cancer cells, which is 3–10 times better than that of CPT. BL_Oc-SS-CPT remained intact during transit to target cells and in normal tissues with a plasma half-life of 4.2 h, 2.3-fold longer than that of the monomer (1.8 h). Once reaching the tumor site, BL_Oc-SS-CPT gradually released CPT in the presence of excessive matrix metalloproteinase-2/9 and GSH in cancer cells. Importantly, BL_Oc-SS-CPT exhibited excellent in vivo tumor targeting capability and antitumor efficacy with benign toxicity profiles. Thus, the novel ETCPP dendrimer-based drug delivery system (e.g., BL_Oc-SS-CPT) represents a safe and effective strategy for targeted cancer therapy.
- 1 August 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 605, 120852
Synthesis and pharmacological evaluation of a novel synthetic peptide CWHTH based on the Styela clava-derived natural peptide LWHTH with improved antioxidant, hepatoprotective and angiotensin converting enzyme inhibitory activities
- 1 August 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 605, 120852
Synthesis and pharmacological evaluation of a novel synthetic peptide CWHTH based on the Styela clava-derived natural peptide LWHTH with improved antioxidant, hepatoprotective and angiotensin converting enzyme inhibitory activities